Latest Chemicals News

Cassius Mining ended the September quarter with A$1.159 million in cash, equivalent to 0.35 quarters of funding at its reported current outgoings. The company is advancing environmental and social studies at its large Madagascar limestone project while awaiting a final Ghana arbitration award and seeking additional funding or a development partner.

Nanollose has narrowed its microbial cellulose scale-up plan to one company-controlled Western Australian pilot facility, with all Stage 1 equipment ordered and paid for. The progress comes with a clear funding constraint: the ASX-listed biomaterials developer ended September with $758,000 in cash, equivalent to 1.41 quarters of funding at its current operating burn.

Bio-Gene Technology has moved closer to two commercialisation milestones, with Qcide product work progressing in Japan and a first Flavocide regulatory submission targeted for Q2 2027. The company ended September with A$2.103 million in cash, equivalent to an estimated 2.18 quarters of funding at the quarter’s operating cash rate.

Australian Vanadium has moved its flagship project closer to an Optimised Feasibility Study while adding new industrial battery opportunities with Alcoa. But the September quarter also reduced cash to $12.4 million, leaving an estimated 2.5 quarters of funding at the reported spending rate.

Vulcan Energy’s first matrix reinjection well delivered an estimated 64 standard litres per second, above the 40-litre assumption underpinning Lionheart’s development plan. The technical progress came alongside €98.0 million of quarterly investing outflows and a cash balance of €129.4 million ahead of expected project debt drawdown in Q1 2027.

Impact Minerals is recasting itself as a high-purity alumina developer, with Lake Hope advancing towards a definitive feasibility study and Alluminous reaching pilot-plant milestones. But the annual report also flags a material uncertainty over funding, while a board refresh and managing director departure add to the company’s transition.

Tissue Repair has increased its US Phase III chronic wound trial to approximately 112 randomised patients while shifting focus towards an April 2027 FDA 510(k) submission. The company also reported $4.74 million in cash, Australian availability of all three TR Pro+ formats and a planned $1 million share buy-back.

Element 25 has moved its Butcherbird manganese expansion into physical execution, targeting mechanical completion in the first quarter of 2027 while pursuing a much larger battery-materials strategy. The company is also positioning a planned Louisiana HPMSM facility as a US$166 million-supported foothold in non-China supply chains, although financing and permitting remain outstanding.

Firebird Metals has secured its first A$1 million ARENA payment and produced 99.999% manganese sulphate as work advances on its Perth demonstration plant. The next test is whether the company can reproduce those results with Oakover ore and move from pilot validation to customer-ready samples.

IGO delivered record Greenbushes spodumene production and a 49% jump in underlying EBITDA in the September quarter, while Nova approaches its final days of operation. The result strengthens the lithium portfolio’s earnings contribution, but Kwinana remains a substantial drag and Greenbushes’ next growth plan is not yet valued.

Green Technology Metals has completed a key environmental assessment for its Seymour lithium project in Ontario, but has pushed the definitive feasibility study into Q1 2027 as it coordinates permitting and consultation. The company ended September with A$7.8 million in cash and reported an estimated 5.4 quarters of funding at the latest burn rate.

Andromeda Metals has lifted independently verified high-purity alumina output to 99.9989% at its continuous pilot plant and sent its first commercial sample to a potential Japanese customer. The result strengthens the technical case for its HPA project, but customer qualification and commercial-scale production remain ahead.